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ABSTRACT 
 
The cochlea has an autonomous circadian clock that controls auditory function and increases 
vulnerability to noise trauma during the active phase. The mechanisms regulating the circadian 
control of the auditory system are poorly understood. Furthermore, it remains unclear whether 
the circadian vulnerability to noise also applies to other auditory insults such as cisplatin, an 
anticancer drug with strong ototoxic side-effects. Here, we investigated the interplay between 
glucocorticoids or glutamate homeostasis and noise- or cisplatin-induced hearing loss in the 
context of circadian influences. Circulating glucocorticoids are important synchronizers of 
clock rhythms and play a role in noise vulnerability. Our results showed that the removal of 
adrenal glands, and the subsequent suppression of circadian glucocorticoid rhythms, rescued 
the increased sensitivity to noise exposure at nighttime.  The greater vulnerability to night-noise 
trauma was associated with a glucocorticoid-dependent regulation of inflammatory genes in the 
cochlea. Dexamethasone, a synthetic glucocorticoid receptor agonist, protected from noise 
damage when administered at daytime, coinciding with endogenous circulating glucocorticoid 
levels being low, but was not equally effective at nighttime, highlighting the relevance of 
considering the time of the day for assessing the effectiveness of a drug. In parallel, we 
hypothesized that disruption of the auditory glutamatergic synapse could exacerbate the 
circadian impact of auditory insults. In a first step, we characterized the synapse status in mice 
lacking the glutamate transporter GLAST and found that GLAST deficient mice have a pre-
existing auditory synaptopathy, which led to an increased sound-evoked activity in the inferior 
colliculus, something that was not seen in wild-type mice. GLAST deficient mice also showed 
greater vulnerability to cisplatin-induced ototoxicity at nighttime, with a near complete loss of 
synaptic coupling to the inner hair cell. This effect could be due to the direct impact of cisplatin 
on the clock machinery since the administration of cisplatin on ex-vivo cochleae at nighttime 
altered the rhythms of the clock protein Period2 in a dose dependent manner. A meta-analysis 
identified five genes that are associated with cisplatin-mediated ototoxicity in cancer patients. 
Four of these were found circadian in the mouse cochlea, also suggesting their involvement in 
the circadian vulnerability to cisplatin. Overall, considering chronopharmacological approaches 
to cisplatin treatment could diminish the adverse side-effects on the auditory system and 
improve the life quality of cancer survivors. 
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1 INTRODUCTION 
1.1 THE AUDITORY SYSTEM 
 
1.1.1 The peripheral auditory system  
 
The inner ear is responsible for encoding sound waves into electrical information, which is then 
conveyed to the central auditory system and leads to sound perception. The cochlea is the 
auditory component of the inner ear, which contains the sensory organ called organ of Corti 
(OC). The function of the cochlea is to transform sound into electrical signals that are then 
transmitted to the brain via the auditory nerve. In the OC, there are two types of sensory cells, 
the inner hair cells (IHC) and the outer hair cells (OHC). There are three rows of OHCs and 
one row of IHCs. IHCs are responsible for detecting sounds and convert mechanical energy 
into nerve impulses and OHCs function as cochlear amplifiers and are controlled by efferent 
nerve activity (Purves, 2018). Sound waves, which are transmitted by the perilymph (extra-
cellular cochlear fluid) cause a displacement in the basilar membrane and subsequently the 
tectorial membrane on which the OHCs are anchored. This movement causes a deflection of 
OHC stereocilia (hair-like bundles of the sensory cells), which modulates their electro-motility 
and amplifies the basilar membrane vibration forcing the stereocilia on the IHCs to become 
deflected, leading to depolarization of the cell and generation of nerve impulses that are relayed 
to the afferent neurons (Purves, 2018). 
The active zone of afferent synapse in mammals is called the synaptic ribbon, first described 
by Smith and Sjöstrand, 1961 and it is found in both hair cell types, OHCs and IHCs (Khimich 
et al., 2005; Smith et al., 1961). The main structural component of ribbons is the protein 
RIBEYE which is involved in the formation of synaptic ribbon scaffold (Schmitz, 2009). The 
ribbon synapses of IHCs are glutamatergic and near 200 vesicles are tethered to each ribbon 
(Moser et al., 2006). Release of glutamate triggers the activation of the α-amino-3-hydroxy-5-
methylisoxazole-4-propionate (AMPA) receptors, made of ionotropic glutamate receptor 
GluR2/3 and GluR4 subunits, in the postsynaptic terminals (Matsubara et al., 1996) and creates 
and action potential that propagates to spiral ganglion neurons (SGN) (Goutman et al., 2015) 
(Figure 1). The SGNs are classified in two types, Type-I and Type-II afferent neurons. Recent 
single-cell RNA-sequencing analyses revealed three novel subclasses of Type-I neurons, Ia, Ib 
and Ic (Petitpre et al., 2018; Shrestha et al., 2018).  
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The stria vascularis (SV) is highly metabolic and provides the cochlea with its blood supply. 
This vascularized epithelial tissue in the lateral wall of the cochlea, consists of three layers of 
cells, the marginal cells, the intermediate cells and the basal cells. The main role of SV is to use 
blood potassium to maintain a high potassium environment with positive endocochlear potential 
(EP) of +80 mV in the endolymph fluid (Patuzzi, 2011; Tasaki et al., 1959). Alterations in the 
EP and the composition of the endolymph can alter the mechanotransduction efficacy and thus 
hearing (Fettiplace, 2017). 
 
1.1.2 The central auditory system 
 
Once the sound waves are transformed to neural signals, they travel through the cranial nerve 
VIII to the structures of the central auditory system where the sound information is further 
processed. The central auditory system is responsible for the tonotopic mapping and the 
decomposition of multi-frequency signals from the cochlea into a spatially organized output 
arranged according to frequencies (Eggermont et al., 2004). Several nuclei, which participate 
in the transmission of the auditory information, are located between the auditory nerve (AN) 
and the auditory cortex (AC): the cochlear nucleus (CN), the superior olivary complex (SOC), 
the lateral lemniscus (LL), the inferior colliculus (IC) and the medial geniculate body (MGB) 
(Purves, 2018). All the information is propagated to these nuclei through synaptic transmission. 
Branching of the nerve fibers, which connect the different nuclei, plays an important role in the 
parallel processing of the auditory system (Peterson et al., 2020).  
Descending pathways of the central auditory system travel in parallel with the ascending 
pathways. These pathways seem to be reciprocal to the ascending, extending from the AC to 
the hair cells. A significant component of the ascending and descending auditory pathways, 
Figure 1: Sound transduction in the 
peripheral auditory system. a) The hair bundle 
on the hair cell is activated by sound induced 
vibrations. The signal is transduced and passed 
via the afferent nerve fiber and the auditory nerve 
towards the brain, where it is perceived as sound. 
b) The signal in the hair cell controls calcium 
channels, causing calcium influx from outside 
the cell. Consequent changes in the cell's active 
zone result in neurotransmitter release into the 
synaptic cleft. Aggregate of neurotransmitter-
containing vesicles are bonded to a structure 
called the synaptic ribbon, localized to 
concentrated sites of calcium influx (Parsons, 
2006). 
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which transfers the general feedback from the AN is the SOC. The SOC is divided into three 
main nuclei: medial superior olive (MSO), lateral superior olive (LSO) and the medial nucleus 
of trapezoid body (Tz). The main function of the SOC is binaural processing and sound 
localization. The MSO detects interaural time differences and the LSO interaural level 
differences in sound levels between the two ears. There are also strong feedback connections 
between primary AC and dorsal cochlear nucleus (DCN), as well as from auditory cortical areas 
via the central nucleus of IC (Coomes et al., 2004). Changes in the cortical activity as a result 
of a damage or inhibition, can lead to direct changes in the subcortical activity of IC and DCN 
and even to indirect changes in the cochlea. Subsequently, DCN can affect the processing of 
lemniscus activity in ventral cochlear nucleus (VCN). Thus, there is a synergy of changes 
happening between the cortex and the brainstem. Hearing injuries or application of ototoxic 
drugs create an imbalance between the excitation and inhibition of the neurons in the cortex 
leading to the reorganization of the tonotopic map, called homeostatic plasticity (Eggermont et 
al., 2004).  
 
1.2 HEARING LOSS 
 
According to the World Health Organization, over 5% of world’s population is suffering from 
disabling hearing loss and this impairment highly affects the quality of life (WHO). Hearing 
impairment is now the 4th leading cause in years lived with disability (Wilson et al., 2017). 
Hearing loss has been shown in many populations to have negative consequences for cognition 
and mental health, as well as is an important risk factor for dementia (Greenzang, 2018; 
Thomson et al., 2017). Noise-induced hearing loss (NIHL) can be divided into temporary and 
permanent and each one of them has different cochlear pathologies. Thresholds can be 
recovered after temporary hearing loss, while permanent hearing loss is usually resulting in hair 
cell and neuronal loss and can lead to severe hearing impairment (Ishii et al., 1998). 
Correspondingly, with increased life expectancy, the prevalence of age-related hearing loss 
(ARHL) is also on the rise (Roth et al., 2011). Both NIHL and ARHL are known as 
sensorineural hearing loss (SNHL) because the dysfunction is initiated in the inner ear’s 
cochlea. For decades, it has been known that hair cell damage is a key contributor in SNHL. 
Emerging evidence also points towards auditory neuron and synaptic damage as a major cause 
for hearing impairment. In addition to NIHL and ARHL, numerous other etiologies of acquired 
hearing loss exist, such as heredity, use of ototoxic medication, bacterial or viral ear infections 
and head injuries (Sha et al., 2017). 
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1.2.1 Noise overexposure 
 
High-level noise affects the hair cells, reduces cochlear blood supply, damages peripheral 
synapses (Henry et al., 1995) and SGNs (Liu et al., 2012), as well as, affects the integrity of 
fibrocytes in the spiral limbus and the spiral ligament, leading in acute and chronic 
rearrangement of central auditory structures (Hirose et al., 2003; Wang et al., 2002). Hair cells 
are more sensitive to noise trauma than the supporting cells. NIHL is known to affect the OHC 
body as well as the stereocilia. The consequence of noise trauma can be OHC loss which can 
be monitored by measuring otoacoustic emissions. The death of OHC from a noise exposure is 
more common than IHC loss (Thorne et al., 1985). This occurs because lower amounts of noise 
are capable of inducing OHC death than what is needed for IHC damage. IHC loss also starts 
to appear when permanent hearing threshold shifts exist (Liberman et al., 1978; Lim, 1976). 
Although OHCs are more prone to death after noise exposure compared to IHCs, their 
stereocilia are less susceptible to noise than the IHC ones (Kaltenbach et al., 1992).  
Furthermore, excitotoxicity that damages glutamate receptors at the afferent synapse leads to 
hearing impairment (Puel et al., 1998). This excitotoxicity likely results from excessive 
presynaptic release of glutamate at the IHC. As a result, the synaptic ribbons are reduced in the 
IHCs after noise exposure (Kujawa et al., 2009). On the other hand, it is evidenced that noise 
exposure causes excitotoxic neural swelling through changes in the mitochondrial activity and 
free radical production and induces both apoptotic and necrotic cell death in the OC (Henderson 
et al., 2006; Le Prell et al., 2007). Reactive oxygen species (ROS) formation has been found in 
marginal cells of SV and in the OHCs (Henderson et al., 2006). Moreover, upregulation of 
endogenous or exogenous antioxidant factors can cause NIHL attenuation (Le Prell et al., 2007). 
In addition, an upregulation of pro-inflammatory cytokines and macrophages during the acute 
phase of inflammation has been found after a noise exposure (Hirose et al., 2005). The sites of 
inflammatory actions are found primarily in the SV, spiral ligament as well as, in the SGNs 
(Hirose et al., 2005; Wang et al., 2002).  
In general, NIHL shows similarities among different animal models, including humans. For 
instance, high sensitivity of OHCs appears to be consistent both in animals and in humans (Lim, 
1976). Differences do however exist in the amount of exposure, the duration, frequency and the 
intensity needed to cause hearing loss. Many rodent models are more sensitive to noise exposure 
compared to humans (Dobie et al., 2017). It is also anticipated that signaling pathways 
underlying NIHL will be preserved among the different species, allowing for therapeutic 
strategies to be successful also in humans (Kujawa et al., 2019).  
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1.2.2 Cisplatin ototoxicity 
 
Cisplatin is a widely used chemotherapeutic agent, mostly effective for solid tumors such as 
lung, head and neck, testicular and ovarian cancer (Sheth et al., 2017). The main reported side 
effects of cisplatin treatment are nephrotoxicity, peripheral neurotoxicity and ototoxicity 
(Callejo et al., 2015). High doses of cisplatin usually affect first the OHCs in the basal part of 
the cochlea (van Ruijven et al., 2005), inducing hearing loss mainly in high frequencies. 
Damage in the upper turn, low frequency region of the cochlea can also happen after high dose 
cisplatin treatment (Lanvers-Kaminsky et al., 2017). This impairs hearing function and can even 
cause deafness. Cisplatin also damages the SV, the SGNs and the supporting cells (Breglio et 
al., 2017). The precise mechanism which is responsible for the auditory impairment in these 
tissues, is not fully understood, but it is assumed that the increased formation of ROS in 
mitochondria followed by collapse of the oxidative metabolism and apoptosis or necrosis, plays 
a significant role in cisplatin ototoxicity (Schacht et al., 2012). Interestingly, it has been recently 
shown that platinum compounds are retained in the SV for a long period (Breglio et al., 2017).  
Cisplatin ototoxicity has been extensively studied in different animal models. It has been shown 
that the mammalian high affinity copper transporter 1 (CTR1), encoded by SLC31A1 gene is a 
membrane protein that plays an essential role in cisplatin uptake (Holzer et al., 2004). On the 
other hand, organic cation transporter 2 (OCT2) has been also identified in the hair cells of OC 
and the cells of SV in mouse cochlea (Ciarimboli et al., 2005) and has been found in pediatric 
cancer patients to be related with otoprotection (Lanvers-Kaminsky et al., 2015). Furthermore, 
there are other mechanisms involved in cisplatin induced ototoxicity and which have been 
presented in experimental animals. P53 and caspase-dependent apoptosis pathway shown to be 
activated in rats when they are exposed to high cisplatin doses (So et al., 2007; Wang et al., 
2004). Additionally, in a recent study, genetic deletion or pharmacological inhibition of p53 in 
adult mice prevents from cisplatin ototoxicity and improves anti-tumor efficacy (Benkafadar et 
al., 2017). In the spiral ligament and in SV of the mouse cochlea, increase of nuclear-factor 
kappa B (NFkB) and induction of nitric oxide synthase (NOS) have been demonstrated after 
systemic cisplatin administration (Watanabe et al., 2002). Additionally, studies in vitro, in HEI-
OC1 cells and in vivo, in mice have identified the involvement of pro-inflammatory cytokines 
such as TNF-α, IL-1β and IL-6 in cisplatin mediated ototoxicity (So et al., 2007).  
In clinical research, the prevalence of cisplatin ototoxicity is more common in pediatric cancer 
patients (Yancey et al., 2012). The incidence of cisplatin induced hearing loss is ranged 
depending on dose, duration, combination of other ototoxic drugs or irradiation, age and gender 
of the patients, nutritional status, pre-existing hearing impairment and time of treatment (Sheth 
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et al., 2017). In addition, genetic predisposition factors related to cisplatin ototoxicity have been 
previously described such as, polymorphisms of antioxidant enzymes (Oldenburg et al., 2007), 
mitochondrial mutations (Peters et al., 2003) and genes involved in DNA repair (Caronia et al., 
2009). However, some polymorphisms were replicated and others not; a comprehensive view 
of the genetic variants increasing the risk of cisplatin ototoxicity is missing. 
 
1.3 COCHLEAR SYNAPTOPATHY 
 
In SNHL, cochlear hair cells are among the most vulnerable elements, where in most of the 
cases, degeneration of their nerve fibers is observed, accompanied by changes in hearing 
thresholds (Wang et al., 2002). In animal models, a delayed loss of SGNs is also detectable (Lin 
et al., 2011). However, recent work in animal models has revealed that hair cell loss and 
upregulated threshold shifts are not always the case of a hearing damage but a hidden hearing 
loss called cochlear synaptopathy can be present in terms of IHC synaptic impairment, damaged 
synaptic transmission to SGNs and disrupted propagation of sound information towards the 
auditory nerve (Kujawa et al., 2015). Synaptic damage associated with a reduction of Wave I 
amplitude of the auditory brainstem response (ABR) has been observed in humans exposed to 
noise (Bramhall et al., 2017). Wave 1 amplitude changes have also been identified in animal 
models of noise, aging and gentamycin (Kujawa et al., 2006; Liberman et al., 2015; Ruan et al., 
2014). To date, the most common measure of synaptopathy is ABR wave 1 amplitude, although 
there have been many debates about its reliability, sensitivity and specificity and if there is 
indeed a direct connection to synaptopathy (Hickox et al., 2017). Several methods to assess 
synaptopathy are under constant development, such as ABR latency (Mehraei et al., 2016), the 
envelope following response (EFR) (Shaheen et al., 2015) and the middle ear muscle reflex 
(Valero et al., 2016). 
 
1.3.1 Glutamatergic neurotransmission and excitotoxicity 
 
A proper glutamatergic neurotransmission is acquired by the fast removal of glutamate, the 
main neurotransmitter of central nervous system, from the synaptic cleft (Niciu et al., 2012; 
Rauen et al., 1998). Glutamate excitotoxicity is defined as cell death resulting from the toxic 
actions, such as excessive stimulation or not adequate clearance of glutamate. The excessive 
efflux of glutamate causes an overactivation of glutamate receptors, which can result in 
neuronal dysfunction and cell death. There are three major types of ionotropic glutamate 
receptors and several classes of metabotropic receptors linked to G-proteins, which are involved 
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in glutamate neurotransmission. The main ionotropic receptors, activated by glutamate, are the 
N-methyl-D-aspartic acid (NMDA), the AMPA and the kainic acid (KA) receptors (Dong et 
al., 2009). Similar excitotoxic environment can be presented in the cochlea. AMPA-type 
glutamate receptors are responsible for neurotransmitters’ release in the IHC synapse (Nouvian 
et al., 2006; Puel, 1995). NMDA receptors are also expressed and localized between the 
synapses of the IHCs and the dendrites of SGNs (Ruel et al., 2008). Excess of glutamate or 
failure of glutamate clearance from the synaptic cleft because of dysfunction of the glutamate 
receptors or transporters, can lead to swelling of synapses and cochlear nerve terminals by 
creating an excitotoxic environment (Pujol et al., 1993). Glutamate excitotoxicity can be 
exacerbated by adding glutamate receptor agonists, after noise exposure or aminoglycoside 
treatment (Kujawa et al., 2009; Ruel et al., 2007). Moreover, a study suggests that IHC 
glutamate excitotoxicity may result from impulse noise trauma (Cho et al., 2013). Generally, 
glutamate excitotoxicity blocks the neural activity and leads to neural degeneration which yields 
synaptopathy or hearing loss (Moser et al., 2013). 
 
1.3.2 Glutamate aspartate transporter (GLAST) 
 
Glutamate plays an important role in the peripheral auditory system and the central nervous 
system as excitatory neurotransmitter, but its abundance can lead to unnecessary excitotoxicity, 
which activates the proper glutamate transporters. Glutamate aspartate transporter (GLAST, 
also known as EAAT1 or SLC1A3), a membrane glycoprotein, which removes excess 
glutamate from the extracellular space (Chen et al., 2017), is expressed in cerebellar astrocytes 
(Takatsuru et al., 2007) specifically in Bergmann glial cells (Schmitt et al., 1997), in cerebral 
neocortex (Kim et al., 2011) and subsequently in the circumventricular organs (Berger et al., 
2000), the retina (Pow et al., 1999) and the inner ear (Furness et al., 1997). GLAST provides 
maintenance of extracellular environment and stabilizes cell-to-cell communication (Jin et al., 
2003). In the cochlea, where it is present, there have been also found 2 more subtypes of Na+-
dependent glutamate transporters: GLT-1 (EAAT2) and EAAC1 (EAAT3) (Chen et al., 2010). 
GLT-1 and EAAC1 have been identified in SGNs (Furness et al., 2003). GLAST is present in 
supporting inner phalangeal cells (IPC) surrounding the IHCs and the afferent neuron synapses, 
in Schwann and satellite cells surrounding the SGNs and in fibrocytes of spiral ligament 
(Furness et al., 2009). It buffers the excess glutamate release at the synapse (Figure 2).  
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Mice lacking GLAST (GLAST KO) exposed to moderate noise levels display a massive 
synaptic swelling due to the incapacity of the supporting cells to pump back the excessive 
glutamate which is released by IHCs (Glowatzki et al., 2006; Hakuba et al., 2000). Furthermore, 
GLAST has also been found to be expressed in human cochlear fibrocytes but not in IPCs 
(Ahmed et al., 2013).   
 
1.4 CIRCADIAN RHYTHMS 
 
The rotation of the earth around its axis and the sun creates a daily (approximately 24 hours) 
and seasonal periodicity, which is regulated by biological clocks. The biological clock 
machinery is an endogenous timing system, capable of generating biological rhythms, called 
circadian (by Latin circa Diem, meaning about a day) even in the absence of environmental 
cues. Molecular clock imposes a temporal organization of key physiological processes such as 
behavior, metabolic function, locomotor activity, cell-cycle, reproduction, immune function, 
cardiovascular and hormonal regulation (Lowrey et al., 2004). The suprachiasmatic nucleus 
(SCN) of the hypothalamus, is the master clock, which acts as a circadian pacemaker, 
synchronizes and coordinates rhythms at the organ level to regulate physiological function 
(Reppert et al., 2002). SCN is unique since it is the only clock that is directly reset by the light 
received via the retinohypothalamic tract (Hannibal et al., 2002). Because of such characteristic, 
it succeeds to maintain the robustness and synchronicity of central and peripheral clocks (Ko et 
al., 2006). The importance of the SCN in synchronizing peripheral organs has been tested in 
the absence of SCN in lesioned animal models, where peripheral tissues become 
desynchronized with time and there is significant loss of clock gene expression (Akhtar et al., 
2002; Terazono et al., 2003).  
GLAST 
Figure 2: Clearance of glutamate from synapse 
through glutamate receptors and GLAST. IHC 
synapse (blue) with SGNs (grey) surrounded by 
supporting cells (green). SGNs express neuregulin 
which is tethered to erbB-receptors, located to the 
supporting cells, promoting the SGN survival. 
Glutamate is released from IHC and cleared by GLAST 
and glutamate receptors (Monzack et al., 2013).  
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In the absence of SCN, glucocorticoids (GC), which are steroid hormones (corticosterone in 
rodents and cortisol in humans) released by the adrenal glands in a circadian manner, become 
arrhythmic (Radziuk, 2013). Their higher expression is appeared in the onset of the active phase 
of each organism (daytime in humans, nighttime in rodents). GCs have been identified in the 
central nervous system and other organs (Androutsellis-Theotokis et al., 2013), but also have 
been detected in the inner ear of animals and humans, both in the cochlear and the vestibular 
part (Erichsen et al., 1996). More specifically, glutamate receptors (GR) have been found in the 
hair cells, supporting cells, spiral ligament and SV, suggesting a potential role in the regulation 
of sensory and non-sensory tissues (Kil et al., 2013).  
In mammals, the generation of circadian rhythms is a cellular process that includes auto-
regulatory transcriptional/translational feedback loops (Albrecht, 2002). The central and 
peripheral clockwork circuitry contains a negative self-regulated feedback loop consisting of 
four transcriptional repressor-encoding genes Per1, Per2, Cry1, Cry2, which are regulated by 
the core loop positive BMAL1-CLOCK protein complexes, which in turn will be repressed by 
PER-CRY complexes resulting in a 24 hour cycle (Albrecht et al., 2003). A secondary 
interlocking loop involves ROR (RORα, RORβ and RORγ), which are activated by BMAL1-
CLOCK complex and REVERB (REVERB-α and REVERB-β) which repress or activate 
Bmal1 and Clock transcription in a circadian manner (Basinou et al., 2017). These core clock 
elements are necessary for the generation and maintenance of circadian rhythms (Kolbe et al., 
2015; Kondratov et al., 2007). 
 
1.4.1 Circadian rhythms in auditory system 
 
The function of the peripheral auditory organ has been shown to be regulated by circadian 
mechanisms. Noise has been found to behave as Zeitgeber time (time keeper) for humans, since 
sound stimulation at nighttime can change circadian rhythms of melatonin and core body 
temperature (Goel, 2005). The adult mouse cochlea was identified to possess a self-sustained 
circadian clock that alters cochlear sensitivity to noise at different times of the day (Meltser et 
al., 2014). Specifically, it has been shown that night noise overexposure affected molecular 
cochlear rhythms more than day noise and this was associated with greater hearing loss (Meltser 
et al., 2014). In support of this finding, previous studies in rodents have identified circadian 
patterns of acoustic startle response (Chabot et al., 1992). Furthermore, antibiotic-mediated 
ototoxicity appears to be circadian influenced, since more damaging outcomes occurring at 
nighttime (Soulban et al., 1990; Yonovitz et al., 1991). Notably, high doses of cisplatin has 
been shown to trigger mortality in a circadian manner, being more toxic at nighttime than 
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daytime and CLOCK has been found to be overexpressed in cisplatin-resistant cells potentially 
playing an important role in multidrug resistance through glutathione-dependent redox system 
(Sun et al., 2017). These studies suggest that cisplatin could have greater impact on cochlear 
function depending on the time of the day it is administered.  
The molecular clock has also been identified in the IC (Park et al., 2016), which plays a 
significant role in noise-induced pathologies (Berger et al., 2014; Salvi et al., 1990). Circadian 
dysfunctions of metabolism, hormone regulation or immune responses, affect the homeostasis 
of the auditory system (Basinou et al., 2017). As it has been evidenced in mouse cochlea, IC is 
also expressing, in a circadian manner core clock gene such as Per1, Per2, Bmal1 and Reverb-
α (Meltser et al., 2014; Park et al., 2016).  
Additionally, it has been shown that the reliability of the distortion product of otoacoustic 
emission (DPOAE) findings in the cochlear function of human volunteers depends on the time-
of-the-day the experiments performed (Cacace et al., 1996). As it seems, the circadian clock 
significantly influences the stimulus frequency, stimulus sound pressure level and the oral 
temperature in humans (Cacace et al., 1996). 
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2 AIMS OF THE THESIS 
 
The main aim of this thesis was to understand the mechanisms by which circadian rhythms 
modulate hearing loss. This was examined by using two different models of auditory insults: 
noise trauma and cisplatin ototoxicity.   
 
The following objectives were addressed:  
 
• The contribution of glucocorticoids in the vulnerability to day or night noise exposure. 
 
• The role of a glutamate transporter (GLAST) on the integrity of the auditory synapse and 
the consequences on the peripheral and central auditory system. 
 
• Whether cisplatin-mediated ototoxicity is influenced by circadian biology in glutamate 
transporter (GLAST) deficient mice. 
 
• A meta-analysis of genetic variants which are associated with cisplatin ototoxicity in 
humans. 
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3 MATERIALS AND METHODS 
 
3.1 EXPERIMENTAL ANIMALS 
 
All experimental animal procedures were performed with the guidelines and the regulations of 
Karolinska Institute and approved by the regional ethical committee (Stockolm’s Norra 
Djurförsöksetiska Nämnd, N156/14 and N140/15). GLAST KO mice, generated by a mix CBA 
x C57Bl/6 background, provided by Dr Tanaka (Otori et al., 1994) were used for noise exposure 
and cisplatin administration, audiological assessment, magnetic resonance imaging and 
molecular evaluation. Mice were 2-6 months old. PERIOD2::LUCIFERASE (PER2::LUC) 
knock-in mice were generated from a C57Bl/6 background (Yoo et al., 2004) and Bmal1 (fx/fx) 
were provided by Dr Bradfield (Bunger et al., 2005). We further crossed Bmal1 with PER2LUC 
mice in order to track cochlear oscillations in the presence or absence of a functional BMAL1. 
PER2::LUC and CBA/Ca/Sca (from Scanbur) mice were used for noise and audiological 
evaluation, adrenalectomy, protein and gene expression analysis profile. Mice were 1-4 months 
old. All mice had ad libitum access to food (Lactamin R34, Lantmännen) and water, were 
housed under a 12:12 h light/dark cycle and the temperature was stable at 19-21℃. Experiments 
in darkness were performed under red light.  
 
3.2  IN VIVO AND EX VIVO PHARMACOLOGICAL TREATMENTS 
 
Mice were treated with intraperitoneal injection (i.p.) 0.5 mg/kg Dexamethasone 21 phosphate 
disodium salt (DEX, Sigma Aldrich, D1159) dissolved in phosphate-buffered saline (PBS) prior 
to noise exposure (Paper I), once per day for 7 consecutive days prior to noise trauma with 0.24 
mmol/kg (30 mg/kg,  200 µl/30 gr body weight) MnCl2 diluted in 0.9 % NaCl (saline) or with 
only 0.9 % NaCl (as a control) (Yu et al., 2005; Grunecker et al., 2010) (Paper II). In parallel, 
mice were treated with 4 mg/kg/day cisplatin (Sigma Aldrich, 479306) for 4 consecutive days 
or nights, diluted in 0.9 % saline or one single dose of 4 mg/kg cisplatin administered either at 
daytime or at nighttime (Paper III). For ex vivo experiments the following drugs were 
administered: 5 µM DEX dissolved in PBS, 25 µM Mifepristone (RU-486, Sigma Aldrich, 
M8046), 5 µM Spironolactone (Sigma Aldrich, S3378) dissolved in ethanol, 5 µM Forskolin 
(Sigma Aldrich, F3917) diluted in PBS (Paper I) and 40-1600 nM cisplatin dissolved in PBS 
(Paper III). 
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3.3 NOISE EXPOSURE AND AUDITORY MEASUREMENTS 
 
Mice were transferred awake inside a 225x120x100 cm3 acoustic chamber, where were placed 
individually. Sham mice were treated alike but in the absence of noise exposure, placed in a 
neighboring soundproof chamber. They were treated with either narrowband noise (6-12 kHz) 
at 100 dB for 1h either at daytime or nighttime (Paper I), or with a narrowband noise (6-12 kHz) 
at 90 dB for 24h, starting at 9 a.m (Paper II). To ensure that no interruptions or fluctuations in 
noise presentation had occurred, noise exposure level was recorded during the whole exposure 
period. After exposure, animals were immediately used either for auditory measurements or 
manganese enhanced-MRI experiments.  
In order to assess hearing quality after noise exposure or cisplatin treatment, we performed 
DPOAE for evaluating the OHC function and ABR for evaluating synapse function between 
IHC and SGN. Mice were anaesthetized with a mixture of ketamine (ketaminol 50 mg/ml, 
Intervet, 511485) and xylazine (Rompum 20 mg/ml, Bayer, KP0A43D), 100 and 10 mg/kg, 
respectively (body weight 200 µl /30 gr) and placed in a custom-made acoustic chamber with 
sound absorbing material. Body temperature was monitored and kept at 37 ℃ during the 
measurements. First, we recorded DPOAEs. The 2f1 − f2 distortion product was measured with 
f2 = 8, 12, 16, 24 kHz, f2/f1 = 1.25, and stimulus levels L1 = L2 + 10 dB SPL. DPOAE 
thresholds were defined as the lowest level of f1 required to produce a DPOAE ≥ -5 dB SPL.  
In consequence, we measured ABRs. For each frequency, sound intensity was decreased from 
90-5 dB SPL in 5 dB steps, until threshold was reached and confirmed with 2 to 3 replicate 
measurements. Threshold was defined as the lowest sound intensity with visually identifiable 
and reproducible waves. Wave 1 amplitude was determined as the difference between the first 
wave peak and its subsequent trough. ABR and DPOAE measurements were performed 5-7 
days prior to noise or cisplatin administration (baseline), 24h and 2 weeks after the trauma. 
Additionally, ABR measurements were performed 2 weeks after operation of adrenalectomy.  
 
3.4 MANGANESE ENHANCED MAGNETIC RESONANCE IMAGING (MeMRI) 
 
Manganese was used as a contrast agent achieving high resolution imaging (70 μm) using the 
following methodology, appropriate for evaluating brain activity. On the 7th day, corresponding 
to the last MnCl2 injection, mice were exposed to the sound or silence for 24h. At the end of 
the exposure, mice were anaesthetized and fixed through cardiac perfusion of 4% cold 
paraformaldehyde (PFA). After being decapitated, heads were placed in 50 ml syringes filled 
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with fomblin oil (SOLVAY, DA 410) and were transferred to the KERIC facility of Karolinska 
Institute for an overnight MRI scanning.  
Insight Toolkit (ITK) Snap software v3.8 (www.itksnap.org) was used for the quantification of 
manganese enhancement following previously reported recommendations (Yushkevich et al., 
2006). Seven anatomical structures related to auditory pathway were identified using the mouse 
brain atlas (Franklin et al., 2008): DCN (- 5.80 mm to - 6.48 mm), Medial Vestibular nucleus 
(MVe, - 5.68 mm to - 6.64 mm), LSO (-5.02 mm to -5.68 mm), Superior Paraolivary nucleus 
(SPO, - 5.02 mm to - 5.52 mm), Tz (-4.84 mm to – 5.68 mm), IC (- 4.16 mm to - 5.34 mm) and 
nucleus of the Central Acoustic Tract (CAT, - 4.60 mm to - 4.96 mm) which were located 
caudally from the bregma along the rostrocaudal axis. An additional structure, the Caudate 
Putamen (CPu, 1.94 mm to -2.30 mm) was identified as a reference independent of sound 
stimulation (Yu et al., 2005).  
 
3.5 SCN ABLATIONS AND ADRENALECTOMY (ADX) 
 
Bilateral lesions of the SCN were performed in a stereotaxic apparatus (World Precision 
Instruments, Sarasota, FL) under ketamine/xylazine anesthesia (i.p. 80 and 14 mg/kg). Lesions 
were made using an electric stimulator (S44, Grass Technologies, Warwick, RI) and stimulus 
isolation unit (SIU5, Grass Technologies). The sham lesioned mice underwent the same 
operation, but no electric current was passed through the electrode. 
To validate the lesions, SCN lesioned mice and sham operated mice were individually placed 
in the Comprehensive Laboratory Animal Monitoring System cages (CLAMS™, Columbus 
Instruments, Columbus, OH). After 24 h of acclimatization to the cages, animals were kept in 
the system for a period of at least 4 consecutive days. Respiratory metabolism was analyzed 
with oxygen consumption (VO2) and respiratory exchange rate (RER).  
Bilateral removal of the adrenal glands was performed in anaesthetized mice (100 mg/kg 
ketamine and 8 mg/kg xylazine) with a dorsal midline incision and lateral retroperitoneal 
incisions. After surgery, skin was sewed and analgesic drug (0.1 mg/kg Temgesic) was given.  
 
3.6 CORTICOSTERONE ELISA  
 
For the assessment of plasma corticosterone levels in ADX or sham mice, blood was collected 
around the clock (6 time points) in heparin coated tubes and centrifuged. Plasma was isolated 
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and corticosterone levels were quantified with and ELISA kit according to the manufacturer’s 
instructions (Corticosterone EIA kit, Enzo, ADI-900-097).  
 
3.7 ORGANOTYPIC CULTURES AND PER2::LUC OSCILLATIONS WITH 
BIOLUMINESCENCE RECORDINGS 
 
Tissues were dissected from PER2::LUC knock-in mice and cultured organotypically on a 
membrane (Millipore, PICMORG50) as previously described (Meltser et al., 2014). Ex vivo 
organs were kept in culture for a minimum of 6 days. The bioluminescence emission from each 
cultured sample was measured for a duration of 1 min every 10th minute with Lumicycle, a 
microplate luminometer equipped with photomultiplier tubes (Actimetrics, Wilmette, IL). 
Parameters of PER2::LUC rhythmicity (amplitude, phase and period) were assessed. Amplitude 
and phase were quantified using Origin software 8.1 SR1 (Microcal Software, Northampton, 
MA, USA) and period was evaluated by using the Lumicycle Analysis program from where we 
extracted the raw values. After one day in the culture, ex vivo tissues either synchronized with 
forskolin or they did not. Consequently, they were treated with drug or PBS (control) either at 
the trough (day 3 of culture) or at the peak (day 3.5) of the oscillation. The drug was washed 
out 3 days later, when fresh culture medium was added. Analysis was done by following the 
protocols already published before (Cederroth et al., 2019; Park et al., 2017). 
 
3.8 INDUCED-COUPLED PLASMA MASS SPECTROMETRY (ICP-MS) 
 
Platinum levels were measured in OC/SGN, SV and blood from GLAST WT and KO, one hour 
after a single injection of 4 mg/kg cisplatin, administered either at daytime (08.00 am) or at 
nighttime (08.00 pm). Mice were euthanized by isoflurane inhalation, followed by decapitation. 
In order to collect plasma samples, blood was obtained from the trunk after decapitation. For 
the tissues processing, the analysis and quantification of platinum compounds, the exact 
protocol of Breglio et al., was followed (Breglio et al., 2017).  
 
3.9 IMMUNOHISTOCHEMISTRY 
 
For immunostaining, mice underwent transcardiac perfusion with 4% PFA and cochleae were 
decalcified in 0.12 M EDTA for 2-3 days. For the demonstration and quantification of 
presynaptic ribbons, postsynaptic glutamatergic AMPA-receptors (GluR2) and their coupling, 
cochlear surface preparations were micro-dissected and stained for a) C-terminal binding 
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protein 2 (mouse (IgG1) anti-CtBP2, 612044 from BD-Biosciences, used at 1:200), b) GluR2 
(mouse (IgG2a) anti-GluA2, MAB397 from Millipore, used at 1:1000) and c) rabbit anti-
Myosin VIIa, (25-6790 from Proteus Biosciences, used at 1:200) to delineate the hair cell 
bodies. Primary antibody incubations were performed overnight at 37oC, followed by 2 hours 
incubation at 37oC with secondary antibodies coupled to Alexa fluor dyes (IgG1 goat anti-
mouse AF568 at 1:500, IgG2a goat anti-mouse AF488 at 1:500 and IgG donkey anti-rabbit 
AF647 at 1:200), correspondingly. Cochlear frequency mapping, for 6, 8, 12, 16, 24, 32, 48 and 
64 kHz along cochlear length, was then performed using a custom plug-in to ImageJ from NIH 
(Measure_Line.class from the Liberman laboratory at the Eaton-Peabody Laboratory). 
Confocal z-stacks along discrete regions of the basilar membrane, capturing synaptic structures 
of around 10 inner hair cells, were made with a 63x oil immersion objective (N.A.1.40) on a 
Zeiss LSM 880 confocal microscope. Image stacks were analysed using Imaris software (x64 
9.2.0, Bitplane AG, Zurich, Switzerland) for the number of ribbons or postsynaptic receptors 
and their pairing.   
 
3.10 QUANTIFICATION OF mRNA TRANSCRIPTS 
 
For the evaluation of mRNA transcript expression patterns at different time points around the 
clock, we performed Quantitative real-time PCR (qRT-PCR), Nanostring nCounter assays and 
RNA sequencing analysis. Detailed description of the above methods is provided in the 
respective papers (paper I and III). In both qRT-PCR and Nanostring analysis, 6 housekeeping 
genes were used for picking of the four more regular references for normalization, which was 
carried out with the geNorm algorithm (Vandesompele et al., 2002).  
 
3.11 STATISTICAL ANALYSIS 
 
All data are presented as mean ± SEM. One or two-way ANOVA with Sidak’s post hoc or 
Bonferroni post hoc test was performed for statistical analysis in GraphPad Prism version 8.0 
software (GraphPad software). Differences which were below 0.05, considered significant and 
depicted with an asterisk (*) on each graph. Reported n is the number of animals/samples 
analyzed.  
 
 24 
 
4 RESULTS AND DISCUSSION 
 
Previous studies in the lab have identified a circadian clock in the mouse cochlea, associated 
with greater vulnerability to noise at nighttime (Meltser et al., 2014). This difference in noise 
sensitivity was related to neurotrophins, which signal the IHC synapse to noise damage. 
However, there is still very little knowledge about what maintains the synaptic integrity. Here, 
we examine the role of GCs in the circadian vulnerability to noise and find that they are involved 
in the auditory recovery from night noise trauma, but unlike neurotrophins, independently from 
synaptic recovery (Paper I). Therefore, we evaluated whether mice lacking glutamate 
transporter GLAST could be more suitable model for investigating the synaptic integrity 
influenced by circadian rhythms, since they have impaired glutamate uptake after noise 
exposure (Hakuba et al., 2000). We observed that indeed GLAST KO mice display 
characteristics of auditory synaptopathy in the absence of noise exposure (Paper II). Since 
glutamate transporters and circadian mechanisms appear to be involved in ototoxicity, we 
investigated whether the two combined could regulate the vulnerability to cisplatin, a major 
anti-cancer drug causing hearing loss. We found that GLAST KO mice are more susceptible to 
cisplatin when administered at nighttime, with a greater loss of synaptic ribbons and synaptic 
coupling (Paper III). We finally performed a systematic review and meta-analysis to identify 
human relevant genes related to cisplatin-mediated ototoxicity, where 8 polymorphisms of 5 
genes were found to be significantly associated (Paper IV). Four of these five genes display 
circadian expression patterns in the cochlea suggesting they could be potentially involved in 
the circadian vulnerability to cisplatin ototoxicity in humans. 
 
4.1 PAPER I: Glucocorticoid removal protects mouse cochlea from night 
noise exposure 
 
In this study, we hypothesized that circadian vulnerability to noise trauma might be influenced 
by GC function, which are clock-controlled and have been shown to modulate auditory 
sensitivity to noise trauma (Canlon et al., 2007). Thus, we investigated the relationship between 
GC rhythms and the cochlear core clock genes in the response to noise trauma. First, we 
confirmed that SCN is responsible for the sustained rhythmicity in the cochlea. Next, we found 
that in the absence of BMAL1 protein there was a decline of ex vivo cochlear rhythmicity, 
which means that cochlear clock requires BMAL1 involvement for conserving a self-sustained 
clock machinery. In order to evaluate the role of GCs, which are established downstream 
mediators of SCN, we performed  adrenalectomy (ADX) in mice and we exposed them to day 
or nighttime noise, where we observed that auditory function, 2 weeks after night noise 
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exposure, was almost fully restored in ADX mice but not in sham mice (Figure 3A). However, 
ADX did not rescue the presynaptic and postsynaptic structures after night noise trauma 
(Figure 3B).  
 
 
These findings pinpoint that GC ablation regulates the cochlear sensitivity to noise trauma at 
nighttime without influencing the presynaptic ribbons. Further, RNA sequencing analysis on 
the whole cochlea revealed genes, which are involved in neurotransmitter signaling and whose 
induction by noise was significant at nighttime, being completely abolished in ADX operated 
mice. In contrast, ADX did not impede gene induction after day noise exposure. In order to 
deepen in the molecular pathways that regulate the circadian vulnerability to noise in the 
absence of GCs, we identified circadian genes, which lost their rhythmicity after ADX, 
suggesting their involvement in the immune system and likely the regulation of inflammatory 
reactions within the cochlea. Last, we investigated the role of DEX, a synthetic glucocorticoid 
agonist, on cochlear rhythms and noise trauma. We observed that DEX has a differential 
outcome on cochlear rhythms depending on the time of the day that is administered. In order to 
evaluate which is the effect of DEX in vivo, we treated mice with DEX prior to day or night 
noise exposure and we found that DEX treatment protected mice exposed to day trauma but not 
to night noise trauma.  
The findings of this study confirm that cochlear circadian rhythms are regulated by Bmal1 and 
present a hierarchical connection between SCN, adrenal glands and the cochlear clock, which 
has never been identified before. The main outcome of this paper is that ADX protects mice 
from night noise damage but without saving the afferent neuron synapse, suggesting that GCs 
mediate the differential sensitivity to day or night noise exposure independently from ribbon 
Figure 3: Endogenous GCs control the vulnerability to night noise exposure without affecting the 
presynaptic ribbons. (A) ABR threshold shifts from sham operated mice (open symbols) and ADX treated 
mice (filled symbols) at 24h and 2 weeks after day (09.00 am_day color) or night (09.00 pm_blue color) 
noise trauma. Results are mean values ± SEM, n = 5–8 (C). *p < 0.05, ** p < 0.01, ***p < 0.001; two-way 
ANOVA with Bonferroni post hoc analysis. (B) Quantification of synaptic ribbons along cochlear 
frequencies from apex to the base from unexposed control mice (black open circles), sham and ADX operated 
after day noise exposure (red circles) and after night noise exposure (blue diamonds), 2 weeks after the 
trauma. Results are mean values ± SEM, n = 1–7. *p < 0.05, **p < 0.01, ***p < 0.001, one-way ANOVA 
with Sidak post-hoc analysis. 
A B 
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counts. Overall, the above findings indicate that the differential response to noise, depending 
on the time of the day, may implicate additional mechanisms, which have not been identified 
yet, such as SGN function or SV regulation. Another interesting observation of this study is the 
role of GCs in the involvement of pro-inflammatory signals including the chemokine Ccl2, 
involved in the trafficking of monocytes. Monocytes have been previously identified in the 
postnatal mouse cochlea (Hirose et al., 2005) but also accumulation of CX3CR1 macrophages 
after acoustic trauma (Sato et al., 2008). Our data suggests that mice are more sensitive to night 
noise because GCs predispose the cochlea to inflammatory reactions.  
The most commonly used agent to treat hearing disorders is DEX (Wei et al., 2013). However, 
in this study we show that the time of the day when the drug is administered plays an essential 
role in determining its efficacy. 
 
4.2 PAPER II: GLAST deficient mice are synaptopathic in the absence of 
noise trauma and show sound-evoked hyperactivity in the IC 
 
Since in the first study we did not find a direct connection between GCs and synaptic damage, 
we sought to exacerbate the vulnerability of auditory synapse using mice deficient for GLAST 
and test its contribution into the circadian regulation of auditory function. Here, in this study, 
we investigated the influence of GLAST loss of function on sound induced brain activity. We 
first examined the hearing characteristics and the cochlear morphology of GLAST KO mice in 
the lack of noise exposure. We observed the pre-existence of cochlear synaptopathy since ABR 
wave 1 amplitude was significantly lower and the number of postsynaptic GluR2 receptors was 
reduced in the GLAST KO mice compared to their WT littermates. We further exposed GLAST 
WT and KO mice to a 24h 90 dB narrow-band noise. After noise exposure, paired synapses 
were almost abolished in the GLAST KO mice showing a clear exacerbation of glutamate 
excitotoxicity. We also assessed sound-evoked responses using MeMRI. The quantification 
presented a greater Mn2+ uptake in the IC of GLAST KO mice when compared to sham exposed 
mice. Such enhancement was not observed in WT mice (Figure 4).  
 27 
 
 
Overall, our study displays evidence of a pre-existing cochlear synaptopathy in GLAST KO 
mice in the absence of noise exposure. This is associated with decreased ABR wave 1 amplitude 
and reduction of paired synapses in the absence of GLAST, despite unaffected ABR and 
DPOAE thresholds. It has been shown that the amount of glutamate levels in the perilymph of 
GLAST KO mice is double, compared to the one in the WT mice, proposing that such 
differences can cause changes in postsynaptic receptors even at baseline levels (Hakuba et al., 
2000). The increased synaptic damage after sound overexposure was related centrally with an 
increased hyperactivity in the IC of GLAST KO mice. Notably, DCN did not present increased 
activity in GLAST KO mice as previously reported in CD-1 mice, although we used very 
Figure 4: Sound evoked hyperactivity in different brain auditory regions of GLAST KO mouse 
identified with MeMRI and quantification of signal enhancement. (A) Representative MeMRI scans of 
GLAST WT and KO mice, sham or noise exposed (90 dB, 24h). Mn2+ uptake was measured in coronal 
sections. Warmer colors presented higher activity in the specific regions. (B) Quantification of the percent 
enhancement of the brain activity in the ascending pathway of auditory system (DCN, MVe, LSO, SPO, Tz, 
IC and CAT) in the GLAST KO compared to the WT mice. All signals normalized to CPu activity. Results 
are mean values ± SEM, n = 9-15, **p < 0.01, two-way ANOVA with Sidak’s post-hoc analysis. 
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similar protocols (Yu et al., 2005). It remains unclear which is the specific contribution of 
GLAST function in the peripheral or central auditory structures.  
 
4.3 PAPER III: Night cisplatin administration induces hearing loss 
accompanied by reduction of ribbons and synapses in GLAST KO mice 
 
In order to investigate the circadian impact on cisplatin ototoxicity in GLAST KO mice, we 
treated them with specific dose of cisplatin (4 mg/kg) for 4 consecutive days, either at daytime 
(09.00 am) or nighttime (09.00 pm). We observed that night cisplatin administration caused 
hearing loss in GLAST KO mice without influencing the OHC function (Figure 5). Wave 1 
amplitude was not affected more from cisplatin treatment since it was already reduced almost 
50% in GLAST KO mice compared to the WT in baseline level, replicating what was shown in 
paper II. Moreover, night cisplatin administration caused greater loss of presynaptic ribbons 
and almost complete synaptic uncoupling in GLAST KO mice (Figure 6).  
 
 
 
The greater impact of night cisplatin treatment on hearing thresholds and synaptic damage was 
not due to higher bioavailability of the drug at night compared to day treatment, which was 
confirmed by performing ICP-MS in the different cochlear compounds and in the blood after 
day or night cisplatin administration. Interestingly, measurements in the blood showed greater 
abundance of platinum compounds after day administration, probably because of reduced 
detoxification in the inactive phase of the mouse. Platinum compounds in the OC/SGN and SV 
Figure 5: Night cisplatin administration upregulates ABR threshold shifts of GLAST KO mice. (A) ABR 
threshold shifts of GLAST WT (open circles) and GLAST KO mice (filled diamonds), 24h and 2 weeks after 
day cisplatin treatment. (B) ABR threshold shifts of GLAST WT and KO mice, 24h and 2 weeks after night 
cisplatin treatment. Results are mean values ± SEM; n=10-13. *p < 0.05; **p < 0.01; ***p < 0.001; two-way 
ANOVA with Sidak’s post hoc analysis. 
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remained the same either after day or night cisplatin treatment. These findings suggest the 
implication of other mechanisms in the higher influence of cisplatin at nighttime on hearing 
function in GLAST KO mice. We were further interested in evaluating whether cisplatin affects 
cochlear clock rhythms. We found that night cisplatin treatment changed the amplitude, phase 
and period of PER2 oscillations, something that did not occur after day cisplatin treatment. 
These findings show that cisplatin impacts on cochlear clock function at nighttime.  
 
 
 
A previously published dataset from our own lab (used in Paper I as well) presented the 
expression of 5 mouse genes that are related to human cisplatin ototoxicity (paper IV). The four 
of these, Acyp2, Lrp2, Sod2 and Tpmt2, which have an antioxidant role, or they are involved in 
metabolism, were found circadian with their peak expression occurring around night onset.  
The findings of this study demonstrate the contribution of glutamate function in the circadian 
sensitivity to cisplatin-induced ototoxicity in mice and especially in the afferent synapse, which 
appears more vulnerable to night cisplatin treatment in mice, in the absence of GLAST. 
Figure 6: Night cisplatin administration reduces synaptic ribbons and completely abolishes synaptic 
pairing in GLAST KO mice. (A) Quantification from confocal images of synaptic ribbons in GLAST KO 
(filled diamonds) and WT (open circles) mice, 2 weeks after day (red) or night (blue) cisplatin treatment. 
Quantification of ribbons in saline treated GLAST KO (diamonds) and WT (circles) mice presented in black. 
(B) Calculation of the number of synaptic pairing in saline treated mice (showed in black), in day cisplatin 
treated group (red) and night cisplatin treated group (blue). Results are mean values ± SEM; n=1-13. *p < 
0.05; **p < 0.01; ***p < 0.001; two-way ANOVA with Sidak’s post hoc analysis. 
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Ototoxicity is a major side effect of cisplatin treatment in cancer patients (Rybak et al., 2007). 
For that reason, the contribution of chronopharmacology in cancer treatment could be important 
and may prove beneficial. We observe that mice with normal glutamate activity are not as 
vulnerable to circadian influences as the mice with glutamate deficiencies. Moreover, the 
obvious decline in paired synapses of GLAST KO mice after night cisplatin treatment was not 
related to similar changes in wave 1 amplitude, suggesting that there is not always a direct 
correlation between synaptic function and wave 1 amplitude as previously described 
(Fernandez et al., 2020; Kujawa et al., 2009). Our findings contrast those reported in rats, where 
cisplatin caused greater damage when administered at daytime (Bielefeld et al., 2018). In 
contrast, they come in agreement with previous studies in mouse brain extracts, where the 
expression of DNA repair protein XPA (xeroderma pigmentosum A) is higher during daytime, 
thus the repair of cisplatin-induced DNA damage is greater during the day (Kang et al., 2009). 
Probably, there are different circadian responses to ototoxic drugs depending on the species to 
which they are administered.  
GLAST protein is not only expressed in IHC/synapse but also in other cochlear structures such 
as the satellite cells of SGNs and in the SV, which leads to the conclusion that additional 
mechanisms may be involved in the circadian vulnerability to cisplatin ototoxicity. While this 
study does not directly address the mechanism(s) underlying circadian cisplatin ototoxicity; 
future studies, leveraging on the models used in Paper I (SCN ablation and ADX), would help 
clarifying the contribution of clock components in the circadian vulnerability to cisplatin 
ototoxicity. 
 
4.4  PAPER IV: Meta-analysis identified genetic polymorphisms associated 
with human cisplatin ototoxicity.  
 
In this study we performed a systematic review followed by a meta-analysis of 30 previously 
published papers where we identified 8 polymorphisms in 5 genes associating with cisplatin 
ototoxicity (Table 1). The interesting observation from this systematic review is that individual 
studies with non-significant findings, when combined, reached enough power, showing an 
increased risk of developing cisplatin ototoxicity. This is the case for LRP2 rs4668123, which 
highlights the need of using larger sample sizes for more robust results.  
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Gene SNP OR CI Low 
 
CI High 
 
Sample 
size 
 
p (X2) 
 
p of 
Fisher 
 
ACYP2* 
 
rs1872328 
 
4.618 
 
3.04 
 
7.02 
 
696 
 
<0.0001  
 
<0.0001 
 
LRP2* 
 
rs4668123 
 
3.53 1.48 
 
8.45 
 
118 
 
0.0026 
 
0.0053 
 
TPMT* 
 
rs12201199 
 
2.822 
 
2.06 
 
3.86 
 
786 
 
<0.0001  
 
<0.0001 
 
LRP2* 
 
rs2075252 
 
2.80 
 
1.25 
 
6.28 
 
118 
 
0.010 
 
0.013 
 
TPMT* 
 
rs1142345 
 
2.618 
 
1.93 
 
3.56 
 
786 
 
<0.0001  
 
<0.0001 
 
TPMT* 
 
rs1800460 
 
2.472 
 
1.82 
 
3.35 
 
786  
 
<0.0001  
 
<0.0001 
 
SOD2* 
 
rs4880  
 
1.917 
 
1.01 
 
3.61 
 
177 
 
0.04 
 
0.05 
 
COMT 
 
rs9332377 
 
1.553 
 
1.18 
 
2.05 
 
847 
 
<0.0001  
 
<0.0001 
 
 
The genes that we identified from repeated studies are mainly involved in antioxidant, 
metabolic or neurological pathways. More specifically, ACYP2 plays a major role in Ca2+ 
homeostasis, which has been shown to participate in hair cell development (Xu et al., 2015). 
The ACYP2 polymorphism showed the greatest risk for cisplatin ototoxicity, which should be 
considered in clinical cancer treatments. LRP2 polymorphisms are also associated with high 
risk of cisplatin ototoxicity. LRP2 or megalin is involved in sensorineural deafness and 
developmental retardation (Khalifa et al., 2015). TPMT, a methyltransferase, has an enzymatic 
activity which varies depending on the polymorphisms of TPMT gene. In this study, three 
polymorphisms of TPMT seem to affiliate with high risk of cisplatin induced ototoxicity. It was 
recently shown that HEI-OC1 cells derived from cochlea are more vulnerable to cisplatin 
treatment in the presence of a variant of Tpmt gene (Bhavsar et al., 2017).  
Furthermore, one polymorphism of COMT has been identified as a significant risk factor. 
Mutations in COMT are involved in sensorineural hearing loss. Generally, there are strong 
indications that catecholamines potentially play a role in auditory function. The last important 
gene involved in cisplatin-mediated ototoxicity, is the antioxidant SOD2, which regulates ROS 
production and modifies mitochondrial function (Brown et al., 2015).  
A genetic predisposition to cisplatin ototoxicity has been clarified and may help finding cancer 
patients, children or adults, with greater ototoxic risk. This could be a significant improvement 
to the discovery and development of otoprotective therapies in combination with cisplatin 
interventions. It is important to maintain cisplatin efficacy in cancer therapies. Thus, knowing 
Table 1: Summary of all human genes and SNPs related to high risk of cisplatin ototoxicity. Genes that 
are followed by an asterisk have been identified as being circadian from mouse cochlea RNAseq data 
from study I.  
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details about genetic predisposition could facilitate the advance of specific pathways being 
involved in protection against cisplatin ototoxicity. 
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5 CONCLUDING REMARKS 
 
In this thesis, I evaluated the factors by which circadian rhythms modulate hearing impairment, 
focusing on two different models of auditory insults: noise exposure and cisplatin ototoxicity. 
This research demonstrated that GC function can modify NIHL at nighttime (the active phase 
of the mouse), possibly through mechanisms that involve inflammatory responses in the 
cochlea. Synaptic uncoupling by noise was not influenced by GCs. Moreover, these results 
highlight the interactions between endogenous and exogenous GCs in response to noise trauma. 
DEX, a synthetic GR agonist, was only effective when administered at daytime, when 
endogenous GC levels are low. Thus, these findings suggest that the appropriate timing of drug 
administration (chronopharmacology) is important for hearing protection.  
The contribution of the glutamate transporter GLAST in auditory function and synaptic 
integrity was further evidenced. Loss of GLAST function led to a reduction of synaptic coupling 
in the absence of noise or cisplatin. Additionally, mice deficient in GLAST, presented elevated 
sound-evoked neural activity in the IC. These findings pinpoint to the fact that GLAST plays 
an essential role in auditory function, and triggers compensatory gain mechanisms in the central 
auditory pathway.  
Moreover, GLAST depletion altered the vulnerability to cisplatin induced ototoxicity 
depending on the time-of-the-day when administered. After night treatment, GLAST deficient 
mice had disrupted pre- and post-synaptic coupling.  
Last, a systematic review and meta-analysis of genetic studies investigating susceptibility to 
cisplatin ototoxicity revealed several polymorphisms associated with cisplatin ototoxicity in 
humans. Four of these genes were identified as being circadian when using the RNAseq data 
from mouse cochlea, suggesting their potential involvement in the circadian vulnerability to 
cisplatin.  
Overall, the results of this thesis highlight different aspects of circadian regulation in the 
auditory system and suggest that a chronopharmacological approach in therapeutic strategies 
may prevent hearing loss following either noise trauma or cisplatin treatment.  
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